NCT01777165已完成2 期
A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery
AbbVie41 个研究点 分布在 2 个国家目标入组 240 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 240
- 试验地点
- 41
- 主要终点
- Number of patients developing acute kidney injury based on the Acute Kidney Injury Network (AKIN) scoring criteria by comparing the ABT-719 dose groups versus placebo group.
研究概览
简要总结
This study will evaluate the safety and efficacy of ABT-719 in preventing acute kidney injury in patients undergoing high risk cardiac surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be male or female, age greater than or equal to 18 years old.
- •Subjects must have stable renal function, per Investigator discretion and no known increase in serum creatinine of greater than or equal to 0.3 mg during the preceding 4 weeks.
- •Subjects with estimated glomerular filtration rate less than or equal to 60 mL/min/1.73 m2 who require intravascular iodinated contrast within 48 hours of the day of surgery, will only be included if there is no known serum creatinine increase greater than or equal to 0.3 mg.
- •Subjects must be undergoing a pre-defined on-pump cardiac surgery meeting one of the following acute kidney injury risk factors:
- •Subject is undergoing combined coronary artery bypass grafting (CABG) surgery and surgery of one or more cardiac valve (valve(s) surgery), or
- •Subject is undergoing surgery of more than one cardiac valve (valves surgery), or
- •Subject is undergoing surgery of the aortic root or ascending part of the aorta, or
- •Subject is undergoing surgery of the aortic root or ascending part of the aorta, combined with coronary artery bypass graft and/or valve(s) surgery, or
- •Subject has an estimated glomerular filtration rate greater than or equal to 16 mL/min/1.73 m2 and less than or equal to 59 mL/min/1.73 m2 as determined by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula at Screening, and is undergoing coronary artery bypass graft or single valve surgery.
排除标准
- •Has an eGFR less than or equal to 15 mL/min/1.73 m
- •Cardiac surgery to be performed without cardiopulmonary bypass.
- •Has ongoing sepsis or history of sepsis within the last 2 weeks or untreated diagnosed infection prior to Screening visit. Sepsis is defined as presence of a confirmed pathogen, along with fever or hypothermia, and hypoperfusion or hypotension.
- •Has known or documented RIFLE "R" or AKIN "Stage I" within the previous 4 weeks.
- •Recently received (within the last 10 weeks) or is anticipated to receive chemotherapy which can interfere with kidney function
研究组 & 干预措施
Arm 1 ABT-719 lower dose
Experimental
干预措施: ABT-719 (Drug)
Arm 2 ABT-719 intermediate dose
Experimental
干预措施: ABT-719 (Drug)
Arm 3 ABT-719 higher dose
Experimental
干预措施: ABT-719 (Drug)
Arm 4 placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients developing acute kidney injury based on the Acute Kidney Injury Network (AKIN) scoring criteria by comparing the ABT-719 dose groups versus placebo group.
时间窗: Up through Day 7
次要结局
- Proportion of subjects developing AKI as defined by the Risk, Injury, Failure, Loss, or ESRD (RIFLE) model(Up through Day 7)
- Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in serum creatinine based estimated glomerular filtration rate (GFR)(Up through Day 60)
- Proportion of subjects developing AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) model(Up through Day 7)
- Changes from baseline (defined as within 24 hours of day 0) in serum creatinine (SCr) and S-Cystatin C at all study visits from baseline to Day 90(Up through Day 90)
- Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in estimated glomerular filtration rate or measured glomerular filtration rate(Up through Day 90)
研究者
研究点 (41)
Loading locations...
相似试验
终止
2 期
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac SurgeryAcute Kidney InjuryNCT01336959Mereo BioPharma91
终止
2 期
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk SurgeryCardiothoracic SurgeryVascular SurgeryNCT01897519AbbVie56
已完成
2 期
An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac SurgeryCardiac SurgeryCoronary Artery BypassValve SurgeryKidney DiseasesAortic AneurysmNCT01256372Action Pharma A/S77
已完成
2 期
A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAMLNCT01994837AbbVie32
已完成
2 期
Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With SunitinibAdvanced Renal Cell CarcinomaNCT00486538AbbVie (prior sponsor, Abbott)53